Cargando…
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques composed mainly of amyloid-β (Aβ) protein. Overproduction or slow clearance of Aβ initiates a cascade of pathologic events that may lead to formation of neurofibrillary tangles, neuronal cell death, and dementia. Although i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918231/ https://www.ncbi.nlm.nih.gov/pubmed/27471697 http://dx.doi.org/10.2147/ITT.S40131 |